We already one this week from JPM to $42, and Bernstein to $44...and now from Goldman:
Goldman hikes price target on Mylan • 11:12 AM
•Goldman raises its price target on Mylan (MYL +1.2%) to $46 from $40, citing "increased confidence in key revenue and earnings drivers."
•Analyst Jami Rubin ups the forecast for 2018 EPS to $4.50 which, although below MYL's own expectations (as derived from its 5-year compound annual growth rate guidance), is above consensus.
•A key driver behind the call: A higher "probability for generic Copaxone and Advair/Seretide."
•Rubin says generic Advair/Seretide could add over $2 to EPS on an unadjusted basis.
Isn't it pleasant to finally read a number of wall street analyst reports that are positively inclined to Mylan's potential. The key is credibility. A characteristic that Mylan management lacked for many of the past eight years. In addition, management never really understood how important it was to have wall street believe that what management promised management would or could follow through with the promises. I still would like to see Coury retire. He is paid too much and I believe he is and will continue to be an obstacle to Mylan shareholders getting maximum value for their investment.
At least we not have to listen to the guy anymore...hated his demeanor and the way he liked to talk down to analysts. Whether she earned her degree fair and square or not, Heather Bresch is a touch of fresh air when compared to the rascal we had before.